

Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

Data Insights: Covid-2019 Monitor

Friday, April 16, 2021

The global scorecard



For more information contact us:

Donald Luskin: 312 273 6766 don@trendmacro.com Thomas Demas: 704 552 3625 tdemas@trendmacro.com

Copyright 2021 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.

The US scorecard

| The ten worst US states | | | | | | | | | | | | | | | |
|--|---|--------|-------|------------------|--|-----------------------|---------------------------------------|---------------|-----------------------|--------------|---------------------------|-------------------------|----------|--|--|
| New cases New Death | | | aths | New in hospital | | Quine cases Quine des | | | aths Qume in hospital | | | Hospital use | ICU use | | |
| MI | +7,191 | MI | + 123 | FR | +205 | CA | 3,711,723 | CA | 60,808 | TX | 230,397 | RI 90% | MI 29% | | |
| NY | +7,029 | CA | +91 | MI | + 124 | TX | 2,843,929 | NY | 51,418 | CA | 225,627 | MA 84% | MD 25% | | |
| Æ | +6,762 | TX | +82 | GA | + 108 | Æ | 2,148,448 | TX | 49,441 | Æ | 157,459 | MD 83% | RI 20% | | |
| PA | +5,093 | R. | +74 | L _ | +54 | NY | 1,980,337 | R. | 34,238 | NY | 120,811 | PA 81% | NY 18% | | |
| NJ | +3,958 | NY | +68 | FL. | +38 | IL Di | 1,292,421 | PA | 25,546 | GA | 96,993 | MO 81% | DC 18% | | |
| L T(| +3,577 | GA | +62 | NJ | +30 | PA | 1,095,321 | NJ | 25,053 | CH | 77,697 | MI 80% | HA 16% | | |
| IX O | +3,060 | NJ | +4/ | ND | +25 | GA | 1,0/9,9/9 | IL O | 23,896 | PA | 77,625 | CI 80% | MIN 16% | | |
| | +3,007 | PA | +44 | | +24 | | 1,048,109 | GA | 19,002 | IL IA/ | 70,990 | IVIN 79% | NU 14% | | |
| | +2,129 | INC II | + 34 | WA M | +21 | | 907,442 0/1 219 | | 10,917 | ΛT | 09,097 50.059 | FL /0% | IA 14% | | |
| INC | + 2,404 | IL | + 656 | 0 | + 10 | NC | 17 108 027 | IVII | 326.706 | ΡL. | 1 186 25/ | | VVV 1370 | | |
| | ++,0+0 | | +000 | | +0+1 | | 17,100,327 | | 020,730 | | 1,100,204 | | | | |
| All states | +74,289 | | +887 | | +776 | All states | 31,495,649 | | 565,289 | | 2,115,580 | All states 70% | 67% | | |
| Top ten | 60% | | 74% | | 83% | Topten | 54% | | 58% | | 56% | Median 71% | 10% | | |
| 100 10.1 | 0070 | | ,. | | 0070 | . op 10.1 | 0170 | | So | me states n | ot reporting | | | | |
| Five most improved US states | | | | | | | | | | | | | | | |
| Fewer da | Fewer daily cases Fewer new deaths Fewer new hospitalizations M | | | | | | | | | Most pop imm | Most pop immunuity growth | | | | |
| MI | -2,158 | | | | CA | -79 | | | M | -93 | | NH | +85 bp | | |
| PA | -1,182 | | | | CK | -28 | | | MD | -69 | | DC | +75 bp | | |
| CT | -907 | | | | NY | -24 | | | KY | -68 | | ME | +74 bp | | |
| ω | -828 | | | | NE | -21 | | | CT | -27 | | DE | +73 bp | | |
| TX | -649 | | | | MO | -20 | | | IN | -26 | | MT | +70 bp | | |
| 350,000 - | | | | | | | | | | | | | - 12.0% | | |
| 000,000 | | | | | | | | | | | | | 121070 | | |
| | | | | | | | | | | | | | | | |
| 300,000 - United States | | | | | | As of Apr 15 | | | | | | - 10.0% | | | |
| 966 957 bn of population infected | | | | | | | | | | | | | 10.070 | | |
| 17.355 bp of population intoted | | | | | | | | | | | | | | | |
| 250,000 - 38.1 median bopulation age | | | | | | | | | 8.0% | | | | | | |
| 육 31,495,649 cases cumulative _ ///// | | | | | | | | | | 0.070 | | | | | |
| 월 200,000 - | | | | | | +/4 | ,289 cases to | зау | | . 1 | | | Cas | | |
| es al | | | | | ··· | o () | | | | | | | e ov at | | |
| / cas | | | | / · | and the second | Cume fata | inty rate 1.79% | | | | | | ality | | |
| a 150,000 - | | | / | | | 2-week fa | atality rate 1.3 | 6% — | | 1 | | $\langle \cdot \rangle$ | rate | | |
| Daily | | | 1 | | | 565,289 death | s cumulative _ | | | | L ' | | 4.0% | | |
| 100.000 - | | | | | | +887 death | ns today | | | | | | - 4.070 | | |
| 100,000 | | | | | | | •••••• | | | | | | | | |
| | | | . / | | | MA | 1 | ٨ | N | | | MAA | 2.0% | | |
| 50,000 - | | | W. | | | M M | MAAAAA | 1AM | | | | | 2.0% | | |
| | | | [m | Mur | n n n N | v — — | A A A A A A A A A A A A A A A A A A A | Ч Ч. М | | | | | Î | | |
| | | | J | V ^r V | ~~~~~ | | 7-da | y moving aver | rage cases | | ~~~~~ | | 0.0% | | |
| Dec 31 Jan 28 Feb 25 Mar 24 Apr 21 May 19 Jun 16 Jul 14 Aug 11 Sen 8 Oct 6 Nov 3 Dec 1 Dec 29 Jan 26 Feb 23 Mar 23 | | | | | | | | | | | | | | | |
| | | | | | Dec 31 Jan 28 Feb 25 Mar 24 Apr 21 May 19 Jun 16 Jul 14 Aug 11 Sep 8 Oct 6 Nov 3 Dec 1 Dec 29 Jan 26 Feb 23 Mar 23 | | | | | | | | | | |

Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations

| US overa |) 001 C | | | | o unu | | Over last o | lav | Immunity | Full | Partial | |
|---|---------------------|-------------|-------------|-------------------------------------|-------------------|-------------|-------------------|----------------------|----------|------------------|----------------|------------|
| 266.33 million doses distributed | | | | | | | +4.68 mill | ion/day | US | 23.5% | 37.6% | |
| 205.72 mil | lion doses | administer | red | | +3.60 million/day | | | | | UK | 12.5% | 47.8% |
| 129.74 million persons partially immunized | | | | | | | +1.93 million/day | | | | 6.1% | 17.1% |
| 81.45 million persons fully immunized | | | | | | | +1.86 milli | ion/day | 4 /0 | Spain | 7.0% | 18.5% |
| 7.77 million shots long-term care residents/staff | | | | | | | +0.001 mi | llion/d ^r | | Germany | 6.4% | 18.4% |
| 77.2% of distributed doses administered | | | | | | | | Moderna | Pfizer | Italy | 7.0% | 16.6% |
| 38.8% of | US pop p | artial | | 24.4% fu | ll immuni | ity | | 44% | 52% | Australia | 0.9% | 0.6% |
| 100% of | LTC parti | al | | 63.9% fu | ll immuni | itý | | | | Israel | 57.3% | 61.7% |
| | | | | | | At today' | s dosing I | oace. | | Canada | 2.3% | 22.1% |
| | | | | | | every Am | erican >1 | 8 immune | e in | Japan | 0.5% | 0.9% |
| | | C+. | ata | | | 67 | day | ` | | Africa | 0.3% | 0.7% |
| | State | | | | | 01 | udy | S | | India | 1.1% | 7.4% |
| | | Immunities | distributed | by Jun 20, 2021 | | | | | | Brazil | 3.8% | 11.7% |
| | | as % pop | ulation** | US achieves adult herd immunity* in | | | | | | Global data diff | ers from sourc | es, timing |
| AK | | Partial i | mmunity | | | | | | | China NA | ME | |
| 53.4% as % population | | | | I I I Udys | | | | | | | 44.5% | |
| 38.8% | 38.8% Full immunity | | | | by May 1. 2021 | | | | | | 46.8% | |
| 30.8% | | as % po | pulation | WIN | ule | | | | | | 30.9% | |
| | | | | 14/0 | e e t | WI | | | | VT | NH | |
| | | | | 39.8% | | | | | | 47.8% | 42.3% | |
| | | | | | | 40.6% | | | | 44.7% | 56.2% | |
| | | - | | | | 26.7% | | | | 29.1% | 26.7% | |
| | WA | ID | MT | ND | MN | IL | MI | | NY | MA | | |
| | 40.6% | 36.6% | 43.1% | 40.1% | 38.8% | 42.1% | 40.9% | | 42.4% | 44.6% | | |
| | 38.6% | 31.2% | 37.2% | 37.1% | 40.5% | 39.8% | 36.7% | | 41.0% | 46.2% | | |
| | 25.4% | 21.6% | 25.9% | 27.9% | 27.0% | 23.3% | 24.3% | | 26.9% | 27.5% | | 1 |
| | OR | NV | WY | SD | IA | IN | UH | PA | NJ | CI | KI | |
| | 40.2% | 37.3% | 42.7% | 47.2% | 40.6% | 37.4% | 40.8% | 43.2% | 41.4% | 48.6% | 43.5% | |
| | 37.0% | 35.0% | 31.8% | 41.9% | 39.4% | 31.9% | 36.5% | 41.3% | 44.2% | 46.4% | 42.7% | |
| | 23.4% | 22.5% | 23.5% | 29.5% | 26.6% | 21.5% | 24.3% | 24.4% | 28.1% | 29.7% | 30.4% | 1 |
| | | | | INE | | NT | VV V | VA | | DE 40.00/ | | |
| | 42.b% | 35.2% | 40.9% | 40.8% | 38.8% | 39.7% | 43.1% | 40.4% | 42.7% | 43.3% | | |
| | 40.8% | 34.2% | 40.2% | 39.4% | 32.0% | 37.5% | 34.1% 25.0% | 40.3% | 40.8% | 39.9% 22 EV | | |
| l | ZZ.170 | ۲7.9% ۸7 | 23.9% | 20.3 % | 21.3% | 20.0% TN | 20.0% | 24.4% SC | 20.9% | 23.0% | | |
| | | 10.2% | 16.8% | A1 5% | 20.0% | 27.8% | 10.2% | 20.3% | 50.1% | | | |
| | | 36.2% | 46.0% | 38.8% | 32.5% | 30.9% | 35.1% | 33.0% | 38.3% | | | |
| | | 23 N% | 30.5% | 21.1% | 20.4% | 10.0% | 23.0% | 21.6% | 21.7% | | | |
| | | 20.070 | 00.070 | 0K | ΙΔ | MS | ΔI | GA | 21.7 /0 | 1 | | |
| | | | | 44.7% | 39.3% | 38.7% | 38.3% | 39.2% | | | | |
| | | | | 36.1% | 30.3% | 28.6% | 29.4% | 31.4% | | | | |
| | | | | 24.6% | 21.9% | 20.1% | 18.2% | 17.3% | | | | |
| HI | | | | TX | 21.070 | 20.170 | 10.2 /0 | 17.070 | FL | ז (| PR | 1 |
| 46.1% | | | | 38.6% | | | | | 42.7% | | 43.3% | |
| 38.2% | | | | 33.8% | | | | | 36.2% | | 29.8% | |
| 26.8% | | | | 21.2% | As of Apr 15 | | | | | | 18.1% | |

Rolling out the vaccines in the US and the world

* Adult herd immunity is 60% of population over 18 years either fully vaccinated or prior tested positive, no overlap

** One dose of Pfizer/Moderna counts as half an immunity, one dose of J&J as a full immunity

Source: <u>CDC</u>, <u>CDC</u>, <u>Our World in Data</u>, TrendMacro calculations







Source: Johns Hopkins, Covid Act Now, TrendMacro calculations



Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

Recommended reading

Jim Jordan's Nuclear 'Rant' Against Dr. Fauci Speaks for Americans Fed Up with Violations of Their Liberty

yle Becker *Becker News* April 15, 2021

<u>I'm a Virus Expert Who Got the J & J Vaccine. I'm Not</u> Losing Sleep.

Angela L. Rasmussen *New York Times* April 15, 2021

<u>Can the Covid Vaccine Protect Me Against Virus</u> <u>Variants?</u>

Tara Parker-Pope *New York Times* April 15, 2021

<u>Czech Republic: Obesity is big factor in fight against</u> <u>COVID-19</u>

Luboš Palata *Deutsche Welle* April 14, 2021

Meme of the day



Vaccine Recalled After Two People Who Took It Fell Down A Manhole And Died

Source: Our beloved clients, and Power Line blog "The Week in Pictures"



The coronavirus <u>case</u> accelerometer... tracking the world's infection curves *Share of infected population from first day with 100 confirmed cases, log scale*

7



The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality*



Source: Johns Hopkins, TrendMacro calculations

Requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in new cases *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Johns Hopkins, TrendMacro calculations

Alt requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in pos tests *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst



Source: Covid Act Now, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations

Patient zero... and then everyone else







Source: Johns Hopkins, TrendMacro calculations



Source: Johns Hopkins, TrendMacro calculations







Impact in other hot-spots



Impact in the BRICs ex-China





Impact in Africa, continued



Source: Johns Hopkins, TrendMacro calculations